Stock Market & Financial Investment News

News Breaks March 19, 2013 06:45 EDT PFE Congress probing how U.S. should be reimbursed for drug creation, NY Times says Lawmakers are beginning to examine whether pharmaceutical companies should grant the government a greater return on its investment for drugs developed as a result of collaboration between the government and companies, according to The New York Times. Democratic Senator Ron Wyden is asking the National Institutes of Health, or NIH, to describe what the public will receive in return for its investment in the anti-arthritis drug Xeljanz, which was jointly developed by Pfizer (PFE) and NIH, the newspaper noted.Reference Link News For PFE From The Last 14 Days Check below for free stories on PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 10:30 EDT PFE Pfizer management to meet with ISI Group Subscribe for More Information 07:41 EDT PFE Pfizer holders should consider Zoetis exchange, says BMO Capital BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. June 18, 2013 09:38 EDT PFE Active equity option families trading on open Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM June 17, 2013 16:00 EDT PFE Options Update; June 17, 2013 Subscribe for More Information 08:36 EDT PFE InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. 07:28 EDT PFE Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 16:00 EDT PFE Options Update; June 14, 2013 Subscribe for More Information 06:45 EDT PFE Zoetis volatility elevated into Pfizer split-off Subscribe for More Information June 13, 2013 16:00 EDT PFE Options Update; June 13, 2013 Subscribe for More Information 07:32 EDT PFE European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 16:02 EDT PFE Options Update; June 12, 2013 Subscribe for More Information 13:31 EDT PFE Mylan could be interested in generic assets split from Pfizer, Bloomberg says 08:28 EDT PFE Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix Subscribe for More Information 08:02 EDT PFE Pfizer wins $2.15B settlement from Teva and Sun for patent infringement Subscribe for More Information June 11, 2013 16:00 EDT PFE Options Update; June 11, 2013 Subscribe for More Information 15:15 EDT PFE Pfizer June volatility at one-year high Subscribe for More Information 07:42 EDT PFE Boston Biotech Conferences to host a conference Subscribe for More Information June 10, 2013 07:40 EDT PFE Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:20 EDT PFE Biomed to host a conference Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.